MEDTRONIC NAVIGATION
Report
- Report Number
- 1723170-2024-03197
- Event Type
- Malfunction
- Date Received
- October 18, 2024
- Date of Event
- September 6, 2024
- Report Date
- October 18, 2024
- Manufacturer
- MEDTRONIC NAVIGATION, INC
- Product Code
- HAW
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- IT
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
A2) PATIENT AGE IS THE MEAN VALUE OF PATIENTS IN THE STUDY. A3) PATIENT GENDER IS THE MAJORITY VALUE OF PATIENT IN THE STUDY. A4) PATIENT WEIGHT NOT AVAILABLE FROM THE SITE. B3) EVENT DATE IS THE ONLINE PUBLISHING DATE OF THE LITERATURE ARTICLE. D4) DEVICE LOT NUMBER, OR SERIAL NUMBER, UNAVAILABLE. G4) 510(K) IS DEPENDENT UPON THE DEVICE MODEL NUMBER AND THEREFORE, UNAVAILABLE. H3,H6) NO PARTS HAVE BEEN RECEIVED BY THE MANUFACTURER FOR EVALUATION. H4) DEVICE MANUFACTURING DATE IS DEPENDENT ON LOT NUMBER/SERIAL NUMBER, THEREFORE, UNAVAILABLE. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.
BATTISTELLI, M., IZZO, A., D¿ERCOLE, M., D¿ALESSANDRIS, Q. G., DI DOMENICO, M., IOANNONI, E., GELORMINI, C., MARTINELLI, R., VALERI, F., GRILLI, F., MONTANO, N. OPTIMIZING SURGICAL TECHNIQUE IN MICROVASCULAR DECOMPRESSION FOR HEMIFACIAL SPASM ¿ RESULTS FROM A SURGICAL SERIES WITH CONTEMPORARY USE OF NEURONAVIGATION AND INTRAOPERATIVE NEUROMONITORING. SURGICAL NEUROLOGY INTERNATIONAL. 2024. 15 (319) DOI: 10.25259/SNI_268_2024 BACKGROUND: MICROVASCULAR DECOMPRESSION (MVD) THROUGH A RETROSIGMOID APPROACH IS CONSIDERED THETREATMENT OF CHOICE IN CASES OF HEMIFACIAL SPASM (HFS) DUE TO NEUROVASCULAR CONFLICT (NVC). DESPITE THE WIDESPREAD OF NEURONAVIGATION AND INTRAOPERATIVE NEUROMONITORING (IONM) TECHNIQUES IN NEUROSURGERY, THEIR CONTEMPORARY APPLICATION IN MVD FOR HFS HAS BEEN ONLY ANECDOTALLY REPORTED. METHODS: HERE, WE REPORT THE RESULTS OF MVD PERFORMED WITH A COMBINATION OF NEURONAVIGATION AND IONM, INCLUDING LATERAL SPREAD RESPONSE (LSR) IN 20 HFS PATIENTS. HFS CLINICAL OUTCOME AND DIFFERENT SURGICAL-RELATED FACTORS, SUCH AS CRANIOTOMY SIZE, SURGICAL DURATION, MASTOID AIR CELL (MAC) OPENING, POSTOPERATIVE CEREBRAL SPINAL FLUID (CSF) LEAKAGE, SINUS INJURY, AND OTHER COMPLICATIONS OCCURRENCE, AND THE LENGTH OF HOSPITALIZATION (LOS) WERE STUDIED. RESULTS: POSTOPERATIVELY, RESIDUAL SPASM PERSISTED ONLY IN TWO PATIENTS, BUT AT THE LATEST FOLLOW-UP (FU) (MEAN: 12.5 ± 8.98 MONTHS), ALL PATIENTS HAD RESOLUTION OF SYMPTOMS. THE MEAN SURGICAL DURATION WAS 103.35 ± 19.36 MIN, AND THE MEAN LOS WAS 2.21 ± 1.12 DAYS. CRANIOTOMY RESULTED IN 4.21 ± 1.21 CM2 IN SIZE. OPENING OF MAC HAPPENED IN TWO CASES, WHEREAS NO CASES OF CSF LEAK WERE REPORTED AS WELL AS NO OTHER COMPLICATIONS POSTOPERATIVELY AND DURING FU. CONCLUSION: MVD FOR HFS IS AN ELECTIVE PROCEDURE, AND FOR THIS REASON, SURGERY SHOULD INTEGRATE ALL TECHNOLOGIES TO ENSURE SAFETY AND EFFICACY. THE DISAPPEARANCE OF LSR IS A CRUCIAL FACTOR FOR IDENTIFYING THE VESSEL RESPONSIBLE FOR NVC AND FOR ACHIEVING LONG-TERM RESOLUTION OF HFS SYMPTOMS. SIMULTANEOUSLY, THE BENEFITS OF USING NEURONAVIGATION, INCLUDING THE ABILITY TO CUSTOMIZE THE CRANIOTOMY, CONTRIBUTE TO REDUCE THE POSSIBILITY OF COMPLICATIONS. REPORTED EVENTS: OPENING OF MAC HAPPENED IN TWO CASES
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 2271394 | MEDTRONIC NAVIGATION | NEUROLOGICAL STEREOTAXIC INSTRUMENT | HAW | MEDTRONIC NAVIGATION, INC | UNK_NAV_SYS |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 59 YR | Male |